Managing Director, D.E. Shaw and Co., L.P.
Vice President for Corporate Engagement, Rose-Hulman Institute of Technology
Professor of Systems Biology, Columbia University
Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Senior health advisor for Esri
Director, Life Sciences Institute, University of Michigan
Founder and Managing Partner, Frazier Healthcare Ventures
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Disruption in biotech can come in different forms, from new technologies that can change the face of medicine, to ideas and initiatives that can challenge the status quo. Boston has both of these in spades, with ambitious biotech startups bent on transforming drug development and industry leaders unafraid to tackle the sector’s toughest issues. But which new companies are forging the most radical paths and are poised to become the biggest disruptors? What is their approach to building a great biotech company, and how are their founders working with leading venture capital investors to pull it off?
Join Xconomy for this annual evening event featuring candid stories from some of New England’s most radical company leaders, founders, and VC backers out to change the game in biotech.
Anne E. Deconinck is Executive Director of the Koch Institute for Integrative Cancer Research at MIT, where she spearheads industrial partnerships, collaborations, outreach efforts, and communications. She was a key member of the multidisciplinary team that led the design, implementation, and launch of the KI in 2007. She later expanded her role to oversee collaborative programs. Anne received her B.Sc. in Biochemistry from King’s College London and her Ph.D. from Oxford University.
Special Guest Speakers
Vicki L. Sato Ph.D., is currently Professor of Management Practice at Harvard Business School. Dr. Sato retired in 2005 from Vertex Pharmaceuticals, where she served as President since 2000. Before joining Vertex, she was Vice President of Research at Biogen, Inc., and served as a member of the Biogen Scientific Board. Currently, Dr. Sato is a member of the Board of Directors of publicly held Bristol Myers Squibb Company, PerkinElmer Corporation, and BorgWarner. She received her AB from Radcliffe College, and her AM and Ph.D. degrees from Harvard University.
Terry McGuire is founding partner of Polaris Partners, bringing more than 25 years of successful early stage investing experience in healthcare and technology companies. As a venture capitalist, Terry has invested in nearly 50 companies which have addressed the needs of more than 60 million patients and saved over 400,000 lives.
Scott Manalis Ph.D., is a professor of biological and mechanical engineering at MIT, where he has been a faculty member since 1999. He was the recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE) from the Department of Defense. He has also been selected by Technology Review as one of 100 innovators under the age of 35 “whose work and ideas will change the world.” Dr. Manalis received his B.S. degree in physics from the University of California at Santa Barbara in 1994, and his Ph.D. degree in applied physics from Stanford University in 1998.
Intellia Therapeutics Story
Nessan Bermingham, Ph.D. is the entrepreneur and Life Sciences investor whose vision and drive made Intellia “one of the top 10 biotech start-ˇups in 2014” according to Nature Biotechnology. He has more than 15 years of experience in Life Sciences investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets.
Jean-Francois Formela is a partner at Atlas Ventures and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. He serves on the boards of Ataxion, Egalet (NASDAQ: EGLT), F-star, IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA), Kyn Therapeutics, Navitor, RaNA Therapeutics, Spero Therapeutics and ZappRx.
Geraldine Hamilton Ph.D., is the President and Chief Scientific Officer of Emulate. The company’s new living system emulates human biology and predicts human response with greater precision and detail than today’s cell culture or animal-based testing approaches. Emulate’s system is being used by industry, government and academia to understand how different diseases, medicines, chemicals and foods affect human health.
Donald Ingber, MD, PhD is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard and a chaired professor at its schools of medicine and engineering. His work spanning biology, engineering, nanotechnology, and translational medicine has led to numerous honors, over 400 publications, 125 patents and the founding of 5 startups.
Registration and Networking: 5:00 – 6:00 pm
Program: 6:00 – 7:45 pm
Networking Reception: 7:45 – 8:45 pm
View the full agenda.
Regular Registration: $150
Startup Special: $110
Student Special: $50
Walk-in Registration: $195